JP Morgan Chase
AUPH icon

JP Morgan Chase’s Aurinia Pharmaceuticals AUPH Stock Holding History

JP Morgan Chase’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-130,700
Closed -$2.99M – 6579
2021
Q4 		$2.99M Buy
+130,700
New +$3.1M ﹤0.01% 3497
2019
Q3 		– Sell
-50,000
Closed -$316K – 5707
2019
Q2 		$316K Hold
50,000
– – ﹤0.01% 4451
2019
Q1 		$325K Hold
50,000
– – ﹤0.01% 4408
2018
Q4 		$341K Hold
50,000
– – ﹤0.01% 4330
2018
Q3 		$332K Buy
+50,000
New +$280K ﹤0.01% 4479

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's AUPH Position: Q2 2026 in Review

JP Morgan Chase reduced its Aurinia Pharmaceuticals (AUPH) stake by 10% in Q2 2026, selling an estimated $517K and leaving 291,351 shares worth $4.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

JP Morgan Chase first reported a position in AUPH in Q4 2019 and has held it in 23 quarters since. The position peaked at $8.33M in Q4 2024. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • JP Morgan Chase held 291,351 shares of Aurinia Pharmaceuticals worth $4.98M as of Q2 2026.
  • JP Morgan Chase sold 32,334 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $517K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3458 holding.
  • JP Morgan Chase first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 23 quarters since.
  • JP Morgan Chase's Aurinia Pharmaceuticals position peaked at $8.33M in Q4 2024.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.